Granulocyte Colony-Stimulating Factor
"Granulocyte Colony-Stimulating Factor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A glycoprotein of MW 25 kDa containing internal disulfide bonds. It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines.
| Descriptor ID |
D016179
|
| MeSH Number(s) |
D12.644.276.374.410.240.350 D12.776.395.240.200 D12.776.467.374.410.240.350 D23.529.374.410.240.350
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Granulocyte Colony-Stimulating Factor".
Below are MeSH descriptors whose meaning is more specific than "Granulocyte Colony-Stimulating Factor".
This graph shows the total number of publications written about "Granulocyte Colony-Stimulating Factor" by people in this website by year, and whether "Granulocyte Colony-Stimulating Factor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 2 | 1 | 3 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 10 | 6 | 16 |
| 2018 | 5 | 4 | 9 |
| 2019 | 3 | 6 | 9 |
| 2020 | 0 | 6 | 6 |
| 2021 | 1 | 3 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Granulocyte Colony-Stimulating Factor" by people in Profiles.
-
Impact of COVID-19 on peripheral blood stem cell mobilization for myeloma patients. Leuk Lymphoma. 2021 12; 62(12):3023-3026.
-
Cyclophosphamide plus etoposide is a safe and effective mobilization regimen in patients with multiple myeloma. Transfus Apher Sci. 2021 Oct; 60(5):103197.
-
The good, the bad and the ugly: G-CSF, ageing and neutrophils-Implications for severe COVID-19. J Leukoc Biol. 2021 06; 109(6):1017-1018.
-
Is It Safe to Use Long-Acting G-CSF for Febrile Neutropenia Prophylaxis in COVID-19 Pandemic? JCO Oncol Pract. 2021 07; 17(7):455-456.
-
Impact of the COVID-19 pandemic on health care activities at a Uruguayan mastology unit. J Cancer Res Ther. 2021 Apr-Jun; 17(2):547-550.
-
Primary Prophylaxis With Biosimilar Filgrastim for Patients at Intermediate Risk for Febrile Neutropenia: A Cost-Effectiveness Analysis. JCO Oncol Pract. 2021 08; 17(8):e1235-e1245.
-
Time to revisit the use of G-CSF after allogeneic haematopoietic cell transplantation in COVID-19 era? Br J Cancer. 2021 03; 124(7):1183.
-
Effect of Recombinant Human Granulocyte Colony-Stimulating Factor for Patients With Coronavirus Disease 2019 (COVID-19) and Lymphopenia: A Randomized Clinical Trial. JAMA Intern Med. 2021 01 01; 181(1):71-78.
-
Immune Stimulation With Recombinant Human Granulocyte Colony-Stimulating Factor for Coronavirus Disease 2019 (COVID-19)-Beware of Blind Spots. JAMA Intern Med. 2021 01 01; 181(1):78-80.
-
Emerging challenges in the evaluation of fever in cancer patients at risk of febrile neutropenia in the era of COVID-19: a MASCC position paper. Support Care Cancer. 2021 Feb; 29(2):1129-1138.